Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe

Published:2011-07 Issue:7 Volume:30 Page:1375-1381
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Roberts Samantha A.¹,Allen Jeff D.²,Sigal Ellen V.³

Affiliation:

1. Samantha A. Roberts ( ) is a science policy analyst at Friends of Cancer Research, in Washington, D.C.

2. Jeff D. Allen is executive director of Friends of Cancer Research.

3. Ellen V. Sigal is chairperson and founder of Friends of Cancer Research.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference21 articles.

1. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

2. STI571 (imatinib mesylate): the tale of a targeted therapy

3. Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma

4. Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer

5. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union;Journal of Cystic Fibrosis;2024-08

2. Harmonizing regulatory market approval of products with high safety requirements: Evidence from the European pharmaceutical market;Health Economics;2024-03-15

3. Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020;Annals of Internal Medicine;2023-10

4. ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology;JCO Oncology Practice;2023-07

5. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019;JAMA Network Open;2022-06-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3